Urinary hepcidin: an inverse biomarker of acute kidney injury after cardiopulmonary bypass?
John R Prowle, Mark Westerman, Rinaldo Bellomo
Current Opinion in Critical Care | LIPPINCOTT WILLIAMS & WILKINS | Published : 2010
PURPOSE OF REVIEW: In this review, we discuss the potential role of urinary hepcidin, a 2.8-kDa hormonal regulator of iron metabolism, as a biomarker of acute kidney injury (AKI) after cardiopulmonary bypass. RECENT FINDINGS: Hepcidin is one of the novel biomarkers of AKI that have been identified using hypothesis-free, proteomic analysis of urine or plasma in patients who develop AKI. Collectively, these markers promise a new era for the early diagnosis and treatment of AKI in the ICU and an understanding of their biological role may also provide mechanistic insights into the pathogenesis of AKI. Although data confirming the association between urinary hepcidin and AKI are as yet limited, w..View full abstract
Dr M.W. is a shareholder, President and CEO of Intrinsic LifeSciences, developer and distributor of an ELISA assay for hepcidin. Dr J.P. and Professor R.B. are named in a US preliminary patent application in conjunction with Dr M.W. Professor R.B. has received consulting fees from Gambro Biosite, Abbott Diagnostics, and Philips Medical Systems, and grant support from Fresenius Kabi, Bard, Pfizer, and Gambro.